Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inspire Drops Epinastine After Phase III Fizzle

This article was originally published in The Pink Sheet Daily

Executive Summary

Non-steroidal nasal spray for allergic rhinitis is the firm’s second casualty this year.

You may also be interested in...



Inspire Extends Treatment In Phase III Trial For Disease-Modifying CF Candidate

Open-label safety extension of earlier Phase III study shows progressive improvement from baseline over time.

Inspire Extends Treatment In Phase III Trial For Disease-Modifying CF Candidate

Open-label safety extension of earlier Phase III study shows progressive improvement from baseline over time.

Inspiring Results For Phase III Disease-Modifying Cystic Fibrosis Drug

Inspire Pharmaceuticals' denufosol showed improvement in FEV1 versus placebo over 24 weeks.

Related Content

Topics

UsernamePublicRestriction

Register

LL1133833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel